menu
    • menu
    [{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Otonomy"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Short Ragweed Pollen Allergen Extract","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"ALK \/ ALK","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ ALK"},{"orgOrder":0,"company":"ALK","sponsor":"Grandpharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Epinephrine Bitartrate","moa":"Adrenergic receptor alpha-1A","graph1":"Immunology","graph2":"Approved","graph3":"ALK","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"ALK \/ Grandpharma","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Grandpharma"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"House Dust Mite Allergen Extract","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Birch Pollen Extract","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Peanut Sublingual Immunotherapy","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Birch Pollen Extract","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ALK \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by ALK

    Menu

    ALK

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birch Pollen Extract

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ALK's European Reg Application for ITULAZAX® for Paediatric Indication Accepted for Review

                            Details : ITULAZAX is a sublingual immunotherapy tablet of allergen extract for immunotherapy to treat pollen-induced allergic rhinitis and/or conjunctivitis.

                            Brand Name : Itulazax

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2024

                            Lead Product(s) : Birch Pollen Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ALK's Application for House Dust Mite SLIT-Tablet in Children Accepted for Review

                            Details : Acarizax is a standardised allergen extract from house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae, for the treatment of house dust mite allergy.

                            Brand Name : Acarizax

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 25, 2024

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peanut Sublingual Immunotherapy

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ALK Completes First Part of Phase 1 Trial with Peanut SLIT-tablet

                            Details : ALK Abello AS is developing sublingual immunotherapy (‘SLIT’) tablets and it is under phase 1 clinical development for the treatment of Peanut Allergy.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 18, 2024

                            Lead Product(s) : Peanut Sublingual Immunotherapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birch Pollen Extract

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Large Phase 3 Clinical Trial Successfully Meets Primary Endpoint, Confirming the Potential of ALK's Tree Table...

                            Details : ITULAZAX is a sublingual immunotherapy tablet of allergen extract for immunotherapy of tree (birch homologous group) pollen-induced allergic rhinitis and/or conjunctivitis.

                            Brand Name : Itulazax

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 11, 2023

                            Lead Product(s) : Birch Pollen Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Large Phase 3 Clinical Trial Successfully Meets Primary Endpoint, Confirming the Potential of ALKs House Dust ...

                            Details : Odactra (dermatophagoides farinae extract & dermatophagoides pteronyssinus extract) is a prescription medicine used for sublingual immunotherapy to treat house dust mite allergies. ACARIZAX® in Europe and a number of international markets and as MITICUR...

                            Brand Name : Odactra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 08, 2023

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Regulatory Filing for House Dust Mite Allergy Tablet Accepted for Review in China

                            Details : Acarizax® (dermatophagoides farinae extract) is an allergy immunotherapy where repeated administration of allergens to allergic individuals is carried to modify the immunological response to allergen to provide sustained protection during subsequent all...

                            Brand Name : Acarizax

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 03, 2023

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves ALK's Odactra® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherap...

                            Details : Odactra (dermatophagoides farinae extract) is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat house dust mite allergies that can cause sneezing, runny or itchy nose, stuffy or congested nose, or itchy and watery eyes...

                            Brand Name : Odactra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 25, 2023

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ALK Spotlights the Impact of Respiratory Allergies on Children at EAACI Congress

                            Details : ACARIZAX (dermatophagoides farinae extract)., a HDM SLIT-tablet is a treatment for house dust mite-induced allergic rhinitis with or without conjunctivitis and allergic asthma that is not well controlled by symptomatic medication.

                            Brand Name : Acarizax

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 03, 2022

                            Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alk Begins Clinical Trial of Its SLIT-tablet for the Treatment of Peanut Allergy

                            Details : ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 27, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ALK

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : House Dust Mite Allergen Extract

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinical Trial Waiver in China Opens Door to 2022 Registration Filing for ALK's Dust Mite Allergy Tablet

                            Details : A waiver from Chinese authorities allows ALK to file for regulatory approval in China without finalising its paused local registration trial for ACARIZAX® (HDM SLIT), tablet for treatment of HDM allergic rhinitis for 12-65 year-olds and HDM allergic ast...

                            Brand Name : Acarizax

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 03, 2022

                            Lead Product(s) : House Dust Mite Allergen Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth